Duchenne Muscular Dystrophy Drug Landscape

As of 2026-11-14, Sarepta’s Elevidys, NS Pharma’s Viltepso, Italfarmaco’s Duvyzat and Catalyst’s Agamree had US approvals, with different eligible populations and regulatory pathways.

Capricor reported on 2026-11-10 that upper-limb decline slowed by 76% after placebo patients switched to deramiocel in the HOPE-3 extension, an open-label cross-period comparison.

Capricor confirmed on 2026-11-10 that the FDA target action date for deramiocel was 2026-11-22; the decision will determine whether cell therapy joins the approved field.

Duchenne Muscular Dystrophy Drug Landscape

Gene therapy, exon skipping, cell therapy and anti-inflammatory approaches serve different populations. Genotype, age, ambulation and endpoints prevent an across-trial efficacy ranking.

Competitive landscape

AssetCompanyMechanism / routeStageIndicationTrial identifierDealLatest developmentSource
Elevidys / delandistrogene moxeparvovecSareptaUSAAV micro-dystrophin gene therapyIntravenousUS approved; restricted populationAmbulatory DMD, age 4+——FDA boxed liver warning and removal of non-ambulatory indication on 2025-11-14fda.gov
Viltepso / viltolarsenNippon Shinyaku / NS PharmaJapan / USExon 53-skipping ASOIntravenousUS accelerated approvalDMD amenable to exon 53 skipping——Clinical benefit requires confirmation; not all-genotype treatmentdailymed.nlm.nih.gov
Duvyzat / givinostatItalfarmaco / ITF TherapeuticsItaly / USHDAC inhibitorOralUS approvedDMD, age 6+——FDA pivotal study: 179 participants; not gene replacementfda.gov
Agamree / vamoroloneCatalyst (North America) / SantheraUS / SwitzerlandModified corticosteroidOralUS approvedDMD, age 2+——Catalyst commercializes in North America; corticosteroid precautions applycatalystpharma.com
deramiocel / CAP-1002CapricorUSAllogeneic cardiosphere-derived cellsIntravenousFDA reviewProposed focus: upper-limb impairment in DMD age >9——Target 2026-11-22; OLE cross-period upper-limb decline 1.56 points less (76%); Nippon Shinyaku dispute ongoingcapricor.com
z-rostudirsen / DYNE-251DyneUSMuscle-delivered exon 51-skipping therapyIntravenousFDA Priority Review; confirmatory Phase 3DMD amenable to exon 51 skipping——Company’s July 29 release set target 2027-01-21; not an approval outcomedynetx.gcs-web.com
JSONCSV

Taiwan and Asia

Nippon Shinyaku’s US subsidiary NS Pharma holds Viltepso for mutations amenable to exon 53 skipping; its accelerated approval requires confirmation of clinical benefit. Capricor’s disclosed dispute with Nippon Shinyaku is a separate rights risk, so historical cooperation is not treated as an uncontested current entitlement. The Japanese program’s eligible genotypes and confirmatory evidence must be assessed separately from broader systemic therapies.